AHA Names Top CVD Advances for 2023

Advances in stroke, a novel antihypertensive, and new evidence that diabetes drugs may offer CVD benefits for those without diabetes are among the top developments in 2023, on the AHA's annual list.

Related Keywords

Minnesota ,United States ,Maryland ,American ,Mariell Jessup ,George Bakris ,Chiadi Ndumele ,Johns Hopkins University In Baltimore ,Nurse Health Study ,Alnylam Pharmaceuticals ,American Heart Association ,International Stroke Conference ,University Of Chicago Medicine ,Health Professionals ,Determinants Of Health ,Chicago Medicine ,Sandra Taler ,Mayo Clinic ,Benefits Seen ,Most Severe Stroke ,New England Journal ,Advances Help Guide Stent Placement ,Anticoagulation Safe ,Stroke With Atrial Fibrillation ,Diabetes Drugs ,Obesity Without ,Fuel Disparities ,Evidence Links Healthy Eating ,Lower Risk ,Health Professionals Follow Up ,Johns Hopkins University ,Invasive Treatment ,Advanced Peripheral Arterial Disease ,Cv Risk ,Cardiovascular Risk ,V Risk Factors ,Cardiovascular Risk Factors ,Cardiovascular Risk Management ,Hypertension ,Thromboembolism ,Stroke Cerebrovascular Accident Cva ,Obesity ,Bese ,Atrial Fibrillation Af ,Afib ,A Fib ,Atrial Fib ,Trial Fibrillation Af ,Trial Fibrillationa Fib ,F Atrial Fibrillation ,Heart Failure ,Heart ,Kidneys ,